| scholarly article | Q13442814 |
| P50 | author | Stuart C. Ray | Q7626381 |
| Lisa N Wasilewski | Q125310332 | ||
| P2093 | author name string | Justin R Bailey | |
| P2860 | cites work | MEGA6: Molecular Evolutionary Genetics Analysis version 6.0 | Q24498082 |
| Human monoclonal antibodies that inhibit binding of hepatitis C virus E2 protein to CD81 and recognize conserved conformational epitopes | Q27469599 | ||
| Mutations that permit efficient replication of hepatitis C virus RNA in Huh-7 cells prevent productive replication in chimpanzees | Q27473004 | ||
| Cell culture-grown hepatitis C virus is infectious in vivo and can be recultured in vitro | Q27473436 | ||
| Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles | Q27477687 | ||
| Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C | Q27478257 | ||
| Hepatitis C Virus Envelope Glycoprotein E2 Glycans Modulate Entry, CD81 Binding, and Neutralization | Q27481012 | ||
| Development of JFH1-based cell culture systems for hepatitis C virus genotype 4a and evidence for cross-genotype neutralization | Q27485386 | ||
| A Point Mutation Leading to Hepatitis C Virus Escape from Neutralization by a Monoclonal Antibody to a Conserved Conformational Epitope | Q27486113 | ||
| Apolipoprotein C1 Association with Hepatitis C Virus | Q27486923 | ||
| Mutations in Hepatitis C Virus E2 Located outside the CD81 Binding Sites Lead to Escape from Broadly Neutralizing Antibodies but Compromise Virus Infectivity | Q27488430 | ||
| Mutational analysis of the hepatitis C virus E1 glycoprotein in retroviral pseudoparticles and cell-culture-derived H77/JFH1 chimeric infectious virus particles | Q27490271 | ||
| Apolipoprotein E but Not B Is Required for the Formation of Infectious Hepatitis C Virus Particles | Q27490474 | ||
| Estimation of the number of nucleotide substitutions in the control region of mitochondrial DNA in humans and chimpanzees | Q27861060 | ||
| Cell entry of hepatitis C virus requires a set of co-receptors that include the CD81 tetraspanin and the SR-B1 scavenger receptor | Q28200972 | ||
| Human monoclonal antibodies to a novel cluster of conformational epitopes on HCV E2 with resistance to neutralization escape in a genotype 2a isolate | Q28482261 | ||
| Human monoclonal antibody HCV1 effectively prevents and treats HCV infection in chimpanzees | Q28483065 | ||
| CD81 is an entry coreceptor for hepatitis C virus | Q29614812 | ||
| CD81 is required for hepatitis C virus glycoprotein-mediated viral infection | Q29619745 | ||
| The prevalence of hepatitis C virus infection in the United States, 1999 through 2002 | Q29619974 | ||
| A Hepatitis C Virus Envelope Polymorphism Confers Resistance to Neutralization by Polyclonal Sera and Broadly Neutralizing Monoclonal Antibodies | Q30383939 | ||
| Ultrastructural analysis of hepatitis C virus particles | Q30540507 | ||
| Clearance of hepatitis C infection is associated with the early appearance of broad neutralizing antibody responses | Q33707246 | ||
| Evidence for cross-genotype neutralization of hepatitis C virus pseudo-particles and enhancement of infectivity by apolipoprotein C1 | Q33934442 | ||
| Selection pressure from neutralizing antibodies drives sequence evolution during acute infection with hepatitis C virus | Q33955998 | ||
| The natural history of hepatitis C virus infection: host, viral, and environmental factors | Q33974693 | ||
| Characterization of the envelope glycoproteins associated with infectious hepatitis C virus | Q34120689 | ||
| Human broadly neutralizing antibodies to the envelope glycoprotein complex of hepatitis C virus | Q34228030 | ||
| Identification of conserved residues in hepatitis C virus envelope glycoprotein E2 that modulate virus dependence on CD81 and SRB1 entry factors | Q34262175 | ||
| Infectivity of hepatitis C virus is influenced by association with apolipoprotein E isoforms. | Q34295937 | ||
| Efficient culture adaptation of hepatitis C virus recombinants with genotype-specific core-NS2 by using previously identified mutations | Q34742954 | ||
| Naturally selected hepatitis C virus polymorphisms confer broad neutralizing antibody resistance | Q35242585 | ||
| Production and characterization of high-titer serum-free cell culture grown hepatitis C virus particles of genotype 1-6. | Q35557533 | ||
| Breadth of neutralization and synergy of clinically relevant human monoclonal antibodies against HCV genotypes 1a, 1b, 2a, 2b, 2c, and 3a. | Q35557994 | ||
| Adaptive Mutations Enhance Assembly and Cell-to-Cell Transmission of a High-Titer Hepatitis C Virus Genotype 5a Core-NS2 JFH1-Based Recombinant | Q35861270 | ||
| Neutralizing antibody response during acute and chronic hepatitis C virus infection | Q35971609 | ||
| CD4+ T-Cell-Dependent Reduction in Hepatitis C Virus-Specific Neutralizing Antibody Responses After Coinfection With Human Immunodeficiency Virus | Q35993488 | ||
| Cooperativity in virus neutralization by human monoclonal antibodies to two adjacent regions located at the amino terminus of hepatitis C virus E2 glycoprotein | Q36506935 | ||
| Characterization of hepatitis C virus recombinants with chimeric E1/E2 envelope proteins and identification of single amino acids in the E2 stem region important for entry | Q36559862 | ||
| Broad Anti-Hepatitis C Virus (HCV) Antibody Responses Are Associated with Improved Clinical Disease Parameters in Chronic HCV Infection | Q36811958 | ||
| A novel PCR assay for quantification of HIV-1 RNA. | Q36827196 | ||
| Mutations that alter use of hepatitis C virus cell entry factors mediate escape from neutralizing antibodies | Q37629584 | ||
| A Diverse Panel of Hepatitis C Virus Glycoproteins for Use in Vaccine Research Reveals Extremes of Monoclonal Antibody Neutralization Resistance. | Q38809451 | ||
| The association of hepatitis C virus glycoproteins with apolipoproteins E and B early in assembly is conserved in lipoviral particles | Q38994081 | ||
| Hepatitis C virus attachment mediated by apolipoprotein E binding to cell surface heparan sulfate | Q39358973 | ||
| Neutralizing antibody-resistant hepatitis C virus cell-to-cell transmission | Q39641797 | ||
| Production of infectious hepatitis C virus in primary cultures of human adult hepatocytes | Q39684938 | ||
| Robust hepatitis C genotype 3a cell culture releasing adapted intergenotypic 3a/2a (S52/JFH1) viruses. | Q40056082 | ||
| Novel functional hepatitis C virus glycoprotein isolates identified using an optimized viral pseudotype entry assay. | Q40098163 | ||
| Diverse hepatitis C virus glycoproteins mediate viral infection in a CD81-dependent manner | Q40530808 | ||
| Flexible and rapid construction of viral chimeras applied to hepatitis C virus. | Q40688888 | ||
| Apolipoprotein E Mediates Evasion From Hepatitis C Virus Neutralizing Antibodies | Q40982695 | ||
| Global burden of hepatitis C: considerations for healthcare providers in the United States | Q42981508 | ||
| Development and characterization of hepatitis C virus genotype 1-7 cell culture systems: role of CD81 and scavenger receptor class B type I and effect of antiviral drugs. | Q42984512 | ||
| Hepatitis C in the United States | Q42992102 | ||
| Vaccination of chimpanzees with plasmid DNA encoding the hepatitis C virus (HCV) envelope E2 protein modified the infection after challenge with homologous monoclonal HCV. | Q42999964 | ||
| Hepatitis C virus cell-cell transmission in hepatoma cells in the presence of neutralizing antibodies | Q43041465 | ||
| Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge | Q43048336 | ||
| Sustained E2 antibody response correlates with reduced peak viremia after hepatitis C virus infection in the chimpanzee | Q45422073 | ||
| P433 | issue | 11 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Hepatitis C virus | Q708693 |
| P304 | page(s) | 2883-2893 | |
| P577 | publication date | 2016-09-21 | |
| P1433 | published in | Journal of General Virology | Q6295245 |
| P1476 | title | Hepatitis C virus resistance to broadly neutralizing antibodies measured using replication-competent virus and pseudoparticles | |
| P478 | volume | 97 |
| Q59350899 | Broadly Neutralizing Antibody Mediated Clearance of Human Hepatitis C Virus Infection |
| Q56395915 | Defining Breadth of Hepatitis C Virus Neutralization |
| Q36290295 | Extra-epitopic hepatitis C virus polymorphisms confer resistance to broadly neutralizing antibodies by modulating binding to scavenger receptor B1 |
| Q53683152 | Glycan Shielding and Modulation of Hepatitis C Virus Neutralizing Antibodies. |
| Q99570687 | HCV Glycoprotein Structure and Implications for B-Cell Vaccine Development |
| Q59357948 | Immunogenetic and structural analysis of a class of HCV broadly neutralizing antibodies and their precursors |
| Q92592914 | Plasma deconvolution identifies broadly neutralizing antibodies associated with hepatitis C virus clearance |
| Q33739145 | Reverse epitope mapping of the E2 glycoprotein in antibody associated hepatitis C virus |
| Q64235940 | Standardized Method for the Study of Antibody Neutralization of HCV Pseudoparticles (HCVpp) |
| Q47236942 | Synergistic anti-HCV broadly neutralizing human monoclonal antibodies with independent mechanisms. |
Search more.